Oct 15
Recently, Schering-Plough Corporation ( SGP ) and Opko Health Inc. ( OPK ) entered into a deal which would enable Opko to acquire the assets of Schering's neurokinin-1 (NK-1) receptor antagonist program. The companies did not disclose the terms of the agreement. NK-1 receptors are mostly found in the brain. However, they are also found in other tissues of the body. Their activation causes a release of neurotransmitters and other signaling molecules that play a key role in controlling naus
Leave a Reply
